In recent years, new therapies, mainly consisting of monoclonal antibodies like daratumumab and isatuximab, have revolutionized the management of patients with multiple myeloma (MM). Despite these advances, MM remains incurable, and patients who have become refractory to the three therapeutic classes of drugs, including proteasome inhibitors, immunomodulators, and monoclonal antibodies, have a particularly poor prognosis, which highlights the need for new treatment strategies. The development of novel immunotherapeutic approaches, such as antibody-drug conjugates, bispecific antibodies, and CAR T-cells, marks a turning point for heavily pre-treated patients, while revolutionizing their future. In this article, we have reviewed the contributions of these therapies to the current treatment landscape.
Keywords
Immunotherapy, relapsed/refractory multiple myeloma, monoclonal antibody, daratumumab, antibody-drug conjugates, bispecific antibodies, CAR-T